All In Biotech

Free tool

FAERS Monitor: Nucynta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203794 or its brand name (Nucynta, Tapentadol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

28,531

Serious

26,313

92% of reports

Hospitalization

3,126

Death reported

19,844

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death11,509
  • toxicity to various agents9,269
  • overdose5,778
  • drug abuse1,400
  • drug dependence962
  • drug withdrawal syndrome neonatal916
  • accidental overdose656
  • drug ineffective583
  • pain485
  • nausea443
  • intentional product misuse350
  • fatigue281
  • dizziness268
  • headache256
  • fall230

Reports by year received

View as table
YearReports
20051
20081
200995
2010142
2011287
2012283
2013213
2014233
2015709
2016819
20172,271
201821,364
2019458
2020386
2021239
2022245
2023245
2024281
2025215
202644

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,628 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug withdrawal syndrome neonatalSignal91648.545.540,003
toxicity to various agentsSignal9,26942.842.1360,597
overdoseSignal5,77820.319.8104,019
accidental overdoseSignal65613.412.57,421
drug abuseSignal1,40012.612.014,738
deathSignal11,50910.09.895,521
drug dependenceSignal9624.44.22,557
intentional product misuseSignal3503.02.7451
pain4850.60.5150
fall2300.50.4110
nausea4430.40.4385
dizziness2680.40.4252
drug ineffective5830.30.3867
headache2560.30.3428
fatigue2810.30.2591

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.